PTC Therapeutics, Inc.
PTC Therapeutics, Inc. (PTCT) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · PTCT · as of Jun 8, 2026
Activity summary
Buy transactions
0
P-Purchase only
Sell transactions
182
12 Months
Buy/Sell ratio
0.00
Buy/Sell (by trades)
Overall sentiment
PTC Therapeutics, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
PTCT insider buying and selling by quarter
PTCT insider selling · PTCT insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · PTCT ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
PTCT executive sell shares · PTCT board member insider trading · PTCT insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| May 15, 2026 | Boulding Mark Elliott EXEC. VP AND CLO | Option | 2,812 | $72K | Form 4 |
| May 15, 2026 | Boulding Mark Elliott EXEC. VP AND CLO | Sale | 2,356 | $170K | Form 4 |
| May 15, 2026 | Boulding Mark Elliott EXEC. VP AND CLO | Sale | 456 | $33K | Form 4 |
| May 13, 2026 | Klein Matthew B. CHIEF EXECUTIVE OFFICER · Director | Award | 12,500 | — | Form 4 |
| May 14, 2026 | Klein Matthew B. CHIEF EXECUTIVE OFFICER · Director | Sale | 679 | $50K | Form 4 |
| May 14, 2026 | Klein Matthew B. CHIEF EXECUTIVE OFFICER · Director | Sale | 7,221 | $528K | Form 4 |
| May 14, 2026 | Klein Matthew B. CHIEF EXECUTIVE OFFICER · Director | Sale | 2,100 | $153K | Form 4 |
| May 14, 2026 | Klein Matthew B. CHIEF EXECUTIVE OFFICER · Director | Sale | 2,572 | $186K | Form 4 |
| May 8, 2026 | Boulding Mark Elliott EXEC. VP AND CLO | Option | 2,740 | $128K | Form 4 |
| May 8, 2026 | Boulding Mark Elliott EXEC. VP AND CLO | Sale | 840 | $66K | Form 4 |
| May 8, 2026 | Boulding Mark Elliott EXEC. VP AND CLO | Option | 800 | $37K | Form 4 |
| May 8, 2026 | Boulding Mark Elliott EXEC. VP AND CLO | Sale | 200 | $16K | Form 4 |
| May 8, 2026 | Boulding Mark Elliott EXEC. VP AND CLO | Sale | 1,900 | $151K | Form 4 |
| May 8, 2026 | Boulding Mark Elliott EXEC. VP AND CLO | Sale | 600 | $48K | Form 4 |
| Apr 21, 2026 | Klein Matthew B. CHIEF EXECUTIVE OFFICER · Director | Sale | 2,850 | $202K | Form 4 |
| Apr 6, 2026 | Boulding Mark Elliott EXEC. VP AND CLO | Option | 2,265 | $89K | Form 4 |
| Apr 6, 2026 | Boulding Mark Elliott EXEC. VP AND CLO | Sale | 822 | $57K | Form 4 |
| Apr 6, 2026 | Boulding Mark Elliott EXEC. VP AND CLO | Sale | 1,443 | $101K | Form 4 |
| Apr 2, 2026 | Golden Lee Scott EVP & CHIEF MEDICAL OFFICER | Sale | 829 | $56K | Form 4 |
| Apr 1, 2026 | Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER | Sale | 39,393 | $2.71M⚡ | Form 4 |
| Apr 1, 2026 | Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER | Sale | 12,530 | $871K | Form 4 |
| Apr 1, 2026 | Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER | Sale | 80 | $6K | Form 4 |
| Mar 24, 2026 | Chutter Jessica Caroline Director | Award | 3,333 | — | Form 4 |
| Mar 24, 2026 | Chutter Jessica Caroline Director | Award | 4,000 | — | Form 4 |
| Mar 11, 2026 | Klein Matthew B. CHIEF EXECUTIVE OFFICER · Director | Award | 12,500 | — | Form 4 |
Boulding Mark Elliott
EXEC. VP AND CLO
Date
May 15
Shares
2,812
Price
$25.69
Value
$72K
Boulding Mark Elliott
EXEC. VP AND CLO
Date
May 15
Shares
2,356
Price
$72.08
Value
$170K
Boulding Mark Elliott
EXEC. VP AND CLO
Date
May 15
Shares
456
Price
$72.67
Value
$33K
Klein Matthew B.
CHIEF EXECUTIVE OFFICER · Director
Date
May 13
Shares
12,500
Price
—
Value
—
Klein Matthew B.
CHIEF EXECUTIVE OFFICER · Director
Date
May 14
Shares
679
Price
$73.06
Value
$50K
Klein Matthew B.
CHIEF EXECUTIVE OFFICER · Director
Date
May 14
Shares
7,221
Price
$73.08
Value
$528K
Klein Matthew B.
CHIEF EXECUTIVE OFFICER · Director
Date
May 14
Shares
2,100
Price
$73.08
Value
$153K
Klein Matthew B.
CHIEF EXECUTIVE OFFICER · Director
Date
May 14
Shares
2,572
Price
$72.46
Value
$186K
Boulding Mark Elliott
EXEC. VP AND CLO
Date
May 8
Shares
2,740
Price
$46.54
Value
$128K
Boulding Mark Elliott
EXEC. VP AND CLO
Date
May 8
Shares
840
Price
$78.23
Value
$66K
Boulding Mark Elliott
EXEC. VP AND CLO
Date
May 8
Shares
800
Price
$46.54
Value
$37K
Boulding Mark Elliott
EXEC. VP AND CLO
Date
May 8
Shares
200
Price
$78.00
Value
$16K
Boulding Mark Elliott
EXEC. VP AND CLO
Date
May 8
Shares
1,900
Price
$79.31
Value
$151K
Boulding Mark Elliott
EXEC. VP AND CLO
Date
May 8
Shares
600
Price
$79.28
Value
$48K
Klein Matthew B.
CHIEF EXECUTIVE OFFICER · Director
Date
Apr 21
Shares
2,850
Price
$70.91
Value
$202K
Boulding Mark Elliott
EXEC. VP AND CLO
Date
Apr 6
Shares
2,265
Price
$39.42
Value
$89K
Boulding Mark Elliott
EXEC. VP AND CLO
Date
Apr 6
Shares
822
Price
$68.91
Value
$57K
Boulding Mark Elliott
EXEC. VP AND CLO
Date
Apr 6
Shares
1,443
Price
$69.75
Value
$101K
Golden Lee Scott
EVP & CHIEF MEDICAL OFFICER
Date
Apr 2
Shares
829
Price
$67.99
Value
$56K
Almstead Neil Gregory
CHIEF TECHNICAL OPS OFFICER
Date
Apr 1
Shares
39,393
Price
$68.89
Value
$2.71M ⚡
Almstead Neil Gregory
CHIEF TECHNICAL OPS OFFICER
Date
Apr 1
Shares
12,530
Price
$69.50
Value
$871K
Almstead Neil Gregory
CHIEF TECHNICAL OPS OFFICER
Date
Apr 1
Shares
80
Price
$70.30
Value
$6K
Klein Matthew B.
CHIEF EXECUTIVE OFFICER · Director
Date
Mar 11
Shares
12,500
Price
—
Value
—
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About PTCT insider trading
PTCT insider trades
PTC Therapeutics, Inc. (PTCT) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Boulding Mark Elliott (EXEC. VP AND CLO), Almstead Neil Gregory (CHIEF TECHNICAL OPS OFFICER), Klein Matthew B. (CHIEF EXECUTIVE OFFICER · Director). Over the past 12 months, 5 insiders have filed transactions with the SEC. PTCT insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For PTC Therapeutics, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
PTCT insider trading · 5 questionsThe insiders of PTC Therapeutics, Inc. (PTCT) include executives and directors such as Boulding Mark Elliott (EXEC. VP AND CLO), Almstead Neil Gregory (CHIEF TECHNICAL OPS OFFICER), Klein Matthew B. (CHIEF EXECUTIVE OFFICER · Director), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026